See the DrugPatentWatch profile for Novarel
Novarel is a brand name for the medication gonadorelin [1]. It is a synthetic hormone that acts similarly to gonadotropin-releasing hormone (GnRH) [2].
What is Novarel used for?
Novarel is used in assisted reproductive technology (ART) to induce ovulation in women who are undergoing fertility treatments [2]. It is administered as part of a treatment cycle to stimulate the release of an egg from the ovary [3].
How does Novarel work?
Novarel works by mimicking the action of natural GnRH produced by the hypothalamus in the brain. GnRH signals the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In women undergoing fertility treatments, a surge of LH triggers ovulation. Novarel, by stimulating LH release, initiates this ovulation process at the optimal time for egg retrieval [2][3].
When does Novarel's patent exclusivity expire?
Information regarding specific patent expiry dates for Novarel, as a brand name for gonadorelin, is not readily available in the provided context. Patent exclusivity for pharmaceutical products is complex and can involve multiple patents for the drug substance, formulation, and method of use. For detailed patent information, resources like DrugPatentWatch.com may offer specific insights [4].
Who makes Novarel?
Novarel is manufactured by Bayer Pharmaceuticals [1].